+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019

  • ID: 4900247
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 59 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • H. Lundbeck AS
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019

Summary

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • H. Lundbeck AS
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
Introduction
Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
Assuage Pharmaceuticals Inc
H. Lundbeck AS
Jeil Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisinicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JLP-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-8001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program
Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study
Sep 13, 2019: Achieve Life Sciences announces final phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and final data from the phase 2b ORCA-1trial
Jul 23, 2019: Achieve Life Sciences extends collaboration with the National Institutes of Health to advance the development of Cytisinicline for Smoking Cessation
Jun 21, 2019: Achieve Life Sciences announces Phase 2b ORCA-1 trial data accepted for oral presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019: Achieve Life Sciences announces statistically significant improvement in quit rates for simplified cytisinicline dosing schedule in phase 2b ORCA-1 dose-selection trial
May 30, 2019: Achieve announces patent granted in the U.S. for novel formulation of Cytisinicline
Apr 24, 2019: Achieve Life Sciences announces last subject, last visit completed in phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
Apr 02, 2019: Achieve Life Sciences announces successful completion of the second and final DSMC review of phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
Feb 22, 2019: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger
Feb 22, 2019: Achieve announces final data from Cytisinicline phase I/II multi-dose, pharmacokinetic and pharmacodynamics (pk/pd) clinical study to be presented at Society for Research on Nicotine & Tobacco Annual Meeting
Feb 20, 2019: Achieve Life Sciences announces completion of enrollment in 254-subject phase 2b trial of Cytisinicline for smoking cessation
Dec 18, 2018: Achieve Announces Update on Cytisinicline Clinical Development Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Assuage Pharmaceuticals Inc, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019
Pipeline by Kyung Dong Co Ltd, H2 2019
Pipeline by Sopharma AD, H2 2019
Pipeline by Suven Life Sciences Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Assuage Pharmaceuticals Inc
  • H. Lundbeck AS
  • Jeil Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll